Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
Latest news on INCYTE CORPORATION
06/22 ELI LILLY AND : New Safety and Long-Term Efficacy Data from Baricitinib Clinical..
06/20 INCYTE : Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arth..
06/20 INCYTE : New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials..
06/16 INCYTE : New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials..
06/15 INCYTE : Analyst and Investor Event to Highlight Clinical Data Presentations fro..
06/15 INCYTE : Updated Data from ECHO-202 Trial of Incyte's Epacadostat in Combination..
06/14 INCYTE : Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arth..
06/09 INCYTE : Researchers at Incyte Corporation Report New Data on Medicinal Chemistr..
06/07 INCYTE : to Present at Upcoming Investor Conferences
06/06 INCYTE CORPORATION : Corporate News Blog - Incyte and Merck Release Phase-1/2 Cl..
06/05 INCYTE : Analyst and Investor Event to Highlight Clinical Data Presentations fro..
06/05 INCYTE : Updated Data from ECHO-202 Trial of Epacadostat in Combination with KEY..
06/04 INCYTE : Merck early-stage study of cancer drug combo shows promise
06/03 INCYTE : Combination of Epacadostat plus Keytruda® (pembrolizumab) Demonstrates ..
05/30 INCYTE CORPORATION (NASDAQ : INCY) Files An 8-K Submission of Matters to a Vote ..
05/25 INCYTE : New Data for Presentation at ASCO 2017 Reinforce Clinical Profile of Ep..
05/25 INCYTE : First Data from Combination of Epacadostat with Opdivo® nivolumab Will ..
05/22 INCYTE : to Present at Upcoming Investor Conferences
05/18 INCYTE : Vaults on Drug Test Results
05/18 S&P 500 MOVERS : Csco, incy
05/18 NASDAQ 100 MOVERS : Csco, incy
05/17 INCYTE : First Data from Combination of Epacadostat with Opdivo® (nivolumab) Wil..
05/17 INCYTE : New Data for Presentation at ASCO 2017 Reinforce Clinical Profile of Ep..
05/04 INCYTE : Management's Discussion and Analysis of Financial Condition and Results..
05/04 INCYTE : reports 1Q loss
05/04 INCYTE CORP : Results of Operations and Financial Condition, Financial Statement..
05/04 INCYTE CORPORATION : Investor Network: Incyte Corporation to Host Earnings Call
05/04 INCYTE CORPORATION (NASDAQ : INCY) Files An 8-K Results of Operations and Financ..
05/04 INCYTE : Reports 2017 First-Quarter Financial Results and Updates on Key Clinica..
05/04 INCYTE : reports strong revenue growth, loss for 1st quarter
04/25 INCYTE : to Present at Upcoming Investor Conferences
04/21 NASDAQ 100 MOVERS : Mat, incy
04/20 INCYTE : Immuno-oncology and Targeted Therapy Clinical Portfolio to be Featured ..
04/20 Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Incyte Corporat..
04/19 Pomerantz Law Firm Investigates Claims On Behalf of Investors of Incyte Corpo..
04/18 INCYTE : to Report First Quarter Financial Results
04/18 INCYTE : FDA stuns Lilly and Incyte with CRL for much-anticipated RA drug barici..
04/18 Lilly and Incyte`s Loss Is AbbVie and Regeneron`s Gain
04/17 INCYTE CORPORATION : (INCY) Slides on FDA Nod
04/17 INCYTE CORP : Other Events (form 8-K)
04/15 ELI LILLY AND : Incyte Say FDA Issues CRL For Baricitinib
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug -- Up..
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug
04/03 INCYTE : and Merck Provide Additional Details on Previously Announced Collaborat..
04/03 S&P 500 MOVERS : Hpe, incy
04/01 INCYTE : INCY) and Merck (MRK) Amplify Anti-tumor Collaboration
03/10 INCYTE : Financial Statements and Exhibits (form 8-K/A)
03/09 INCYTE : Raises Awareness for Myeloproliferative Neoplasms as Part of Rare Disea..
03/09 INCYTE : Targeted Therapy and Immuno-oncology Portfolio to be Featured in 20 Abs..
03/09 Bull market turns 8 - historical facts and figures
03/06DJINCYTE : Race Tightens for Next Wave of Cancer Drugs
03/02 INCYTE : Announces Oncology Research Alliance with the Abramson Cancer Center at..
03/02 INCYTE : Targeted Therapy and Immuno-oncology Portfolio to be Featured in 20 Abs..
02/28 INCYTE : Raises Awareness for Myeloproliferative Neoplasms as Part of Rare Disea..
02/26 INCYTE : announces collaboration with Penn cancer center
02/24 NASDAQ 100 MOVERS : Bidu, incy
02/24 INCYTE : and Agenus Amend Collaboration Agreement
02/24 ELI LILLY AND : European Commission Approves Once-Daily Olumiant Tablets for Tre..
02/24 ELI LILLY AND : Additional results from pivotal RA-BEAM study published in New E..
02/23 INCYTE : Announces Oncology Research Alliance with the Abramson Cancer Center at..
02/23 INCYTE : University of Pennsylvania Announces Cancer Research Alliance with Incy..
02/21 INCYTE : to Present at Upcoming Investor Conferences
02/21 INCYTE CORPORATION (NASDAQ : INCY) Files An 8-K Entry into a Material Definitive..
02/21 INCYTE CORP : Entry into a Material Definitive Agreement, Unregistered Sale of E..
02/16 ELI LILLY AND : EC approves Eli Lilly's rheumatoid arthritis drug
02/15 INCYTE : Additional results from pivotal RA-BEAM study published in New England ..
02/15 AGENUS INC. (NASDAQ : AGEN) Files An 8-K Entry into a Material Definitive Agreem..
02/15 INCYTE CORPORATION (NASDAQ : INCY) Files An 8-K Results of Operations and Financ..
02/15 INCYTE CORPORATION (NASDAQ : INCY) Files An 8-K Entry into a Material Definitive..
02/14 INCYTE CORP : Entry into a Material Definitive Agreement, Regulation FD Disclosu..
02/14 INCYTE : Management's Discussion and Analysis of Financial Condition and Results..
02/14 NETWORKNEWSBREAKS – AMENDED CO : AGEN), Incyte Corp. (NASDAQ: INCY) Shares..
02/14 INCYTE : INCY) Gains on Agenus Deal
02/14 NASDAQ 100 MOVERS : Logm, incy
02/14 INCYTE CORP : Results of Operations and Financial Condition, Financial Statement..
Advertisement
Financials ($)
Sales 2017 1 427 M
EBIT 2017 -61,4 M
Net income 2017 -135 M
Finance 2017 268 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018 326,19
EV / Sales 2017 19,3x
EV / Sales 2018 16,7x
Capitalization 27 774 M
More Financials
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | INCY | US45337C1027 | 4-Traders
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 147 $
Spread / Average Target 8,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
David W. Gryska Chief Financial Officer & Executive Vice President
Reid M. Huber Chief Scientific Officer & Executive VP
Steven H. Stein Chief Medical Officer & Senior Vice President
Paul Alan Brooke Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION33.63%27 774
QUINTILES IMS HOLDINGS..19.50%19 614
LONZA GROUP26.33%15 927
CELLTRION, INC.--.--%12 175
SEATTLE GENETICS, INC.19.86%9 027
ALKERMES PLC5.58%8 989
More Results